News from DURECT Corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 22, 2017, 07:00 ET DURECT Completes Enrollment in PERSIST, Phase 3 trial for POSIMIR®

DURECT Corporation (Nasdaq: DRRX) today announced that patient enrollment has been completed in PERSIST, the pivotal Phase 3 clinical trial of...


Jun 19, 2017, 07:00 ET DURECT's Collaboration with Sandoz Clears HSR Review and is Effective

DURECT Corporation (Nasdaq: DRRX) today announced that the previously disclosed development and commercialization agreement with Sandoz AG, a...


May 10, 2017, 16:05 ET DURECT Corporation Announces First Quarter 2017 Financial Results and Provides Corporate Update

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2017 and provided a corporate update....


May 08, 2017, 07:00 ET DURECT and Sandoz have Signed a $293 Million Development and Commercialization Agreement for POSIMIR® (SABER®-Bupivacaine) Covering the United States

DURECT Corporation (Nasdaq: DRRX) today announced a development and commercialization agreement with Sandoz AG, a division of Novartis (NYSE: NVS),...


May 04, 2017, 16:30 ET DURECT Corporation Invites You to Join its First Quarter 2017 Earnings Conference Call

In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2017 financial results press release, you are invited to listen to a...


Apr 24, 2017, 08:00 ET DURECT Announces Presentation of Data from a Phase 1b Study of DUR-928 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017

DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company actively developing new therapeutics based on its Epigenetic Regulator Program and...


Apr 17, 2017, 08:00 ET DURECT to Present Clinical Data at the International Liver Congress™ 2017

DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company actively developing new therapeutics based on its Epigenetic Regulator Program and...


Apr 03, 2017, 07:30 ET DURECT to Present at the H.C. Wainwright NASH Investor Conference

DURECT Corporation (Nasdaq: DRRX) announced today that Jim Brown, President and Chief Executive Officer, will be presenting at the H.C. Wainwright...


Mar 14, 2017, 16:02 ET DURECT Corporation Announces Fourth Quarter and Full Year 2016 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2016 and provided a corporate...


Feb 24, 2017, 16:55 ET DURECT Corporation Invites You to Join its Fourth Quarter 2016 Earnings Conference Call

In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2016 financial results press release, you are invited to listen to a...


Jan 30, 2017, 08:00 ET DURECT Corporation Announces Update on DUR-928 Development Program

DURECT Corporation (Nasdaq: DRRX) today provided an update on the DUR-928 development program. DUR-928, our Epigenetic Regulator Program's lead...


Oct 31, 2016, 16:03 ET DURECT Corporation Announces Third Quarter 2016 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2016. Total revenues were $3.7 million and net loss...


Oct 31, 2016, 16:02 ET DURECT Corporation Announces Update on DUR-928 Development Program

DURECT Corporation (Nasdaq: DRRX) today provided an update on the DUR-928 development program including a description of data from the first cohort...


Oct 21, 2016, 16:30 ET DURECT Corporation Invites You to Join its Third Quarter 2016 Earnings Conference Call

In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2016 financial results press release, you are invited to listen to a...


Sep 26, 2016, 07:05 ET DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER (oxycodone) Extended-Release Capsules CII

 DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has received a Complete Response Letter...


Sep 06, 2016, 08:00 ET DURECT to Present at the Rodman & Renshaw Global Investment Conference

DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at the Rodman & Renshaw Global...


Jul 25, 2016, 17:29 ET DURECT Corporation Invites You to Join its Second Quarter 2016 Earnings Conference Call

 In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2016 financial results press release, you are invited to listen to a...


Jul 01, 2016, 09:05 ET DURECT Provides REMOXY® Update

DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has announced that the U.S. Food and Drug...


Jun 28, 2016, 16:30 ET DURECT to Present at the Cantor Fitzgerald Healthcare Conference

 DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Cantor Fitzgerald...


May 31, 2016, 08:30 ET DURECT to Present at the Jefferies Healthcare Conference

 DURECT Corporation (Nasdaq: DRRX) announced today that Jim Brown, President and Chief Executive Officer, will be presenting at the Jefferies...


May 19, 2016, 09:05 ET DURECT Announces FDA Advisory Committee Meeting for REMOXY®

DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has announced that an Advisory Committee of...


May 11, 2016, 09:05 ET DURECT Announces New REMOXY® Data being Presented at American Pain Society Meeting

DURECT Corporation (Nasdaq: DRRX) today announced researchers will present new data around REMOXY's abuse-deterrent properties at the 35th Annual...


May 05, 2016, 16:05 ET DURECT Corporation Announces First Quarter 2016 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2016.  Total revenues were $3.6 million and net...


Apr 29, 2016, 12:15 ET DURECT Announces Closing of Public Offering of Common Stock

DURECT Corporation (Nasdaq: DRRX) today announced the closing of an underwritten public offering of 13,800,000 shares of its common stock, offered...


Apr 28, 2016, 16:30 ET DURECT Corporation Invites You to Join its First Quarter 2016 Earnings Conference Call

 In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2016 financial results press release, you are invited to listen to the...